Antibodies News and Research

RSS

NOVAVAX completes pre-clinical safety and efficacy study of its RSV vaccine candidate

Novavax, Inc. announced today that it has successfully completed a pre-clinical safety and efficacy study of its RSV vaccine candidate in cotton rats. Results from this study are needed to support an Investigational New Drug (IND) application to advance this novel recombinant F protein particle based RSV (RSV-F) vaccine candidate into clinical development. This vaccine candidate is composed of recombinant 'F' or 'fusion' protein of RSV which is used by the virus to infect and fuse with cells in the respiratory tract and cause disease.

13 Jan 2010

Life Technologies to acquire AcroMetrix

Life Technologies Corporation, a provider of innovative life science solutions, today announced that it has signed a definitive agreement to acquire AcroMetrix, for an undisclosed amount.

12 Jan 2010

Pfizer/Medivation's AD drug Dimebon may garner peak year sales of $1.5 billion

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, if Pfizer/Medivation's Dimebon shows efficacy in two ongoing clinical trials in moderate to severe Alzheimer's disease that is equivalent to the impressive clinical trial data it has already shown to date in mild to moderate patients, these positive data would promote the use of Dimebon throughout the course of the disease.

12 Jan 2010

MRCT announces licensing deal for development of novel therapy for inflammatory and immune diseases

Georg-August-University Gottingen, University of Regensburg and MRC Technology (MRCT) have signed exclusive license agreements through MBM ScienceBridge GmbH and in agreement with Bayerische Patentallianz GmbH, for the development of a novel therapy of inflammatory and immune diseases based on the depletion of inflammatory monocytes. The first targets will be rheumatoid arthritis (RA) and multiple sclerosis (MS).

12 Jan 2010

Millipore introduces new Viresolve Pro+ Solution

Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced the availability of its new Viresolve® Pro+ Solution, an innovative virus filtration product that further extends the company’s leadership in the rapidly growing and highly regulated virus safety market.

12 Jan 2010

Sorrento Therapeutics, Scripps Research Institute announce antibody development collaboration

Sorrento Therapeutics, Inc. today announced an antibody discovery and development collaboration with The Scripps Research Institute, La Jolla, CA. Under the terms of the agreement, Sorrento Therapeutics obtains an exclusive, worldwide license to the Institute's novel technology, based on quorum sensing, for the prevention and treatment of Staphylococcus aureus ('Staph') infections, including Methicillin-resistant Staph. aureus (MRSA).

12 Jan 2010

PET-CT imaging appears to detect cancer in patients with neurologic complications

A combined positron emission tomography-computed tomography (PET-CT) scan of the whole body appears to detect cancer in individuals with related neurologic complications more accurately than some other commonly used tests, according to a report posted online today that will appear in the March print issue of Archives of Neurology, one of the JAMA/Archives journals.

12 Jan 2010

Neoprobe submits IND amendment to FDA for RIGScan CR radiopharmaceutical

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, announced today that it has submitted an investigational new drug (IND) amendment to the United States Food and Drug Administration (FDA) which includes the design of a proposed Phase 3 clinical trial of Neoprobe’s RIGScan® CR radiopharmaceutical.

12 Jan 2010

YM BioSciences announces results of cancer antibody-radionuclide conjugate development collaboration

YM BioSciences Inc. today announced results of a collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The approach has successfully concluded its first series of proof-of-principle experiments establishing promise for future development and application.

12 Jan 2010

AnaptysBio, Roche sign agreement for development of novel antibody therapeutics

AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced it has signed an agreement with Roche for the development of novel antibody therapeutics.

12 Jan 2010

NexMed updates corporate activities

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today provided an update on ongoing corporate activities and the status of the Company’s NASDAQ listing.

9 Jan 2010

LFB completes conversion of all acquired preferred stock

GTC Biotherapeutics, Inc. announced that LFB Biotechnologies, a wholly owned subsidiary of LFB S.A. (Laboratoire Français du Fractionnement et des Biotechnologies S.A., Les Ulis, France) and a strategic shareholder in GTC, has converted the convertible preferred stock it previously purchased in November 2009 under the terms described in the financing agreements approved by GTC shareholders in July 2009 into a total of 5.3 million shares of common stock.

9 Jan 2010

Pall introduces new prepacked chromatography columns for faster protein purification process

Pall Corporation, a global leader in filtration, separation and purification, announces the launch of 5 mL PRC prepacked chromatography columns to deliver faster and more consistent protein purification processing.

From Pall Corporation 8 Jan 2010

Laureate Pharma and Iconic Therapeutics complete manufacturing hI-con1 recombinant Fc-Factor VII fusion protein

Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company specializing in the development and GMP manufacture of monoclonal antibodies, fusion proteins and other therapeutic protein products, and Iconic Therapeutics, a company focused on the development of treatments for wet adult macular degeneration (wet AMD) and other ophthalmic diseases, today announced the completion of the manufacture of the first GMP lot of hI-con1(TM) recombinant Fc-Factor VII fusion protein.

8 Jan 2010

Prolias acquires UMBI's technology to develop human therapeutic antibodies

Prolias, a biotechnology company working to discover and develop novel therapeutic proteins and antibodies for treatment of disease, today announced a strategic acquisition of technology from the University of Maryland Biotechnology Institute (UMBI).

7 Jan 2010

UMBI announces exclusive licensing of fully human antibody technology platform to Prolias

The University of Maryland Biotechnology Institute (UMBI) today announced the exclusive licensing of a fully human antibody technology platform to Prolias, a biotechnology company working to discover and develop novel therapeutic proteins and antibodies for treatment of disease.

7 Jan 2010

Flu vaccine safe but ineffective for RA patients treated with rituximab

Rheumatoid arthritis (RA) patients are partially protected by the influenza vaccine 6-10 months after treatment with rituximab. Researchers determined that while the flu vaccine is safe, it is ineffective for RA patients in the first 6 months following rituximab treatment.

7 Jan 2010

SDI to discover biomarkers in collaboration with Fred Hutchinson Cancer Research Center

SDI (Strategic Diagnostics Inc.), a provider of biotechnology-based products and services, and Fred Hutchinson Cancer Research Center (the Hutchinson Center) today jointly announced they will collaborate to discover biomarkers for use in the early detection of a variety of cancers.

7 Jan 2010

MabCure signs clinical research agreement to diagnose ovarian cancer

MabCure, N.V. (“MabCure”) a wholly-owned subsidiary of MabCure Inc., a biotech company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, has signed a clinical research agreement with the Ramathibodi Hospital, Mahidol University in Bangkok, Thailand.

7 Jan 2010

Innexus Biotechnology designs new psoriasis product

InNexus Biotechnology Inc. (TSX.V: IXS) (www.ixsbio.com), a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the development of a new psoriasis product based on its proprietary dermal permeating Transmab™ technology.

6 Jan 2010

Antibodies News and Research

NOVAVAX completes pre-clinical safety and efficacy study of its RSV vaccine candidate

Life Technologies to acquire AcroMetrix

Pfizer/Medivation's AD drug Dimebon may garner peak year sales of $1.5 billion

MRCT announces licensing deal for development of novel therapy for inflammatory and immune diseases

Millipore introduces new Viresolve Pro+ Solution

Sorrento Therapeutics, Scripps Research Institute announce antibody development collaboration

PET-CT imaging appears to detect cancer in patients with neurologic complications

Neoprobe submits IND amendment to FDA for RIGScan CR radiopharmaceutical

YM BioSciences announces results of cancer antibody-radionuclide conjugate development collaboration

AnaptysBio, Roche sign agreement for development of novel antibody therapeutics

NexMed updates corporate activities

LFB completes conversion of all acquired preferred stock

Pall introduces new prepacked chromatography columns for faster protein purification process

Laureate Pharma and Iconic Therapeutics complete manufacturing hI-con1 recombinant Fc-Factor VII fusion protein

Prolias acquires UMBI's technology to develop human therapeutic antibodies

UMBI announces exclusive licensing of fully human antibody technology platform to Prolias

Flu vaccine safe but ineffective for RA patients treated with rituximab

SDI to discover biomarkers in collaboration with Fred Hutchinson Cancer Research Center

MabCure signs clinical research agreement to diagnose ovarian cancer

Innexus Biotechnology designs new psoriasis product

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo